Subscribe
istock-ciphotos-istockphoto-com665048016-1-
CIPhotos / iStockphoto.com
31 January 2019Americas

Celgene signs $1bn deal to develop blood cancer therapy

Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.

More on this story

Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB